Daina Graybosch
Stock Analyst at Leerink Partners
(1.27)
# 3,722
Out of 5,139 analysts
98
Total ratings
41.18%
Success rate
-7.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IPSC Century Therapeutics | Downgrades: Market Perform | $7 → $2 | $2.17 | -7.83% | 5 | Nov 17, 2025 | |
| IPHA Innate Pharma | Downgrades: Market Perform | $10 → $2 | $1.74 | +14.74% | 11 | Sep 18, 2025 | |
| XLO Xilio Therapeutics | Initiates: Outperform | $2 | $0.64 | +212.45% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $1.96 | +257.14% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $17.04 | -29.58% | 1 | Jun 11, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $108.83 | +9.34% | 19 | Jan 13, 2025 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $6.36 | +214.47% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $68.94 | -43.43% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $37.68 | +19.43% | 10 | Feb 24, 2023 | |
| FATE Fate Therapeutics | Maintains: Outperform | $62 → $10 | $1.19 | +740.34% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $21.80 | +74.31% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $4.20 | +90.48% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $109.00 | +105.50% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.04 | +1,370.59% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $0.55 | +2,994.85% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $2.36 | +281.36% | 4 | Feb 25, 2022 |
Century Therapeutics
Nov 17, 2025
Downgrades: Market Perform
Price Target: $7 → $2
Current: $2.17
Upside: -7.83%
Innate Pharma
Sep 18, 2025
Downgrades: Market Perform
Price Target: $10 → $2
Current: $1.74
Upside: +14.74%
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $2
Current: $0.64
Upside: +212.45%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $1.96
Upside: +257.14%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $17.04
Upside: -29.58%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $108.83
Upside: +9.34%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $6.36
Upside: +214.47%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $68.94
Upside: -43.43%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $37.68
Upside: +19.43%
Fate Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $1.19
Upside: +740.34%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $21.80
Upside: +74.31%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $4.20
Upside: +90.48%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $109.00
Upside: +105.50%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.04
Upside: +1,370.59%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $0.55
Upside: +2,994.85%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $2.36
Upside: +281.36%